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Lessons Learned About Prostatic Transformation
from the Age-Related Methylation of
5a-Reductase Type 2 Gene
John T. IsaacsFrom The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Brady Urologic Institute, The Johns Hopkins School of Medicine,
Baltimore, MarylandA nearly universal plight among aging males throughout
the world is the hyperplastic growth of the transition zone
within the prostate, known as benign prostatic hyperplasia
(BPH).1 With approximately 50% of males throughout the
world developing BPH, it is the most common neoplasia
in humans. Although the etiology of BPH is not fully
resolved, it is known that its maintenance requires a
continuous supply of androgen. This is documented by the
observation that testicular suppression via luteinizing
hormone releasing hormone superagonist reversibly re-
duces prostatic size and clinical BPH symptoms.2 Like-
wise, the normal prostate is dependent on adequate
chronic androgenic stimulation for both its fetal devel-
opment and adult maintenance.3Supported by NIH grants P50CA058236 and P30CA006973.
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In both BPH and normal prostate, androgen stimulation
requires irreversible conversion within the prostate of circu-
lating testosterone into the more potent androgen, dihy-
drotestosterone, via enzymatic activity of 5a-steroid
reductase (SRD5A). There are at least three SRD5A genetic
isoforms expressed within the prostate4,5; however, only
germline inheritance of loss-of-function mutations in the
SRD5A2 gene is known to retard normal prostate develop-
ment, thus preventing BPH.3 On the basis of these observa-
tions, orally active drugs (eg, ﬁnasteride and dutasteride),
which reversibly inhibit SRD5A1 and irreversibly inhibit
SRD5A2 enzyme,6 have been clinically developed for the
treatment of BPH. Chronic daily treatment with these
5a-reductase inhibitors results in a decrease in prostate size by
approximately 25% within 4 to 6 months and is further
associated with improvement in clinical symptoms.7,8Copyright ª 2015 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2015.01.001Interestingly, approximately 30% of patients do not respond
to such chronic 5a-reductase inhibitor treatment.7,8
This overall response rate is intriguing because Niu et al9
reported that prostatic expression of the SRD5A2 gene is vari-
able and similarly absent in one third of aging men with BPH
and that this down-regulation is associated with hyper-
methylation of CpG islands in the promoter of SRD5A2 gene
detected using methylation-speciﬁc pull-down PCR. In the
current issue of The American Journal of Pathology, this group
proposes an inﬂammation-driven process involving DNA
methyltransferase 1edependent tumor necrosis factor-a/NF-
kB/IL-6 signaling pathway as a mechanism for such epigenetic
silencing of the SRD5A2 gene in BPH.10 In this study, tran-
surethral resected BPH tissue from patients without 5a-reduc-
tase inhibitor treatment was analyzed. Therefore, the study
limits assessingwhether the hypermethylation of SRD5A2 gene
may identify patients who will lack clinical response to inhibi-
tion of 5a-reductase. To address this important clinical issue,
needle biopsy tissue could be analyzed from BPH patients who
are administered 5a-reductase inhibitors to test prospectively if
SRD5A2 gene hypermethylation may predict clinical response.What Does Hypermethylation of the SRD5A2
Gene Inform About Prostatic Neoplasia?
The determination of whether hypermethylation of SRD5A2
gene may predict clinical response to treatment with
Commentary5a-reductase inhibitor will be signiﬁcant. CpG island
hypermethylation of gene regulatory elements is common in
cancers (eg, CpG hypermethylation of the 50 promoter region
of pi-class glutathione-S-transferase gene is themost common
and earliest genetic change in human prostate carcinogen-
esis11). Until recently, it was not appreciated that in many
tissues, stochastic methylation drift occurs in many genes
during aging because of the imperfect maintenance of
epigenetic marks of methylation driven by chronic inﬂam-
mation.12 This drift generates epigenetic mosaicism in aging
stem cells. Although the methylation-speciﬁc pull-down
PCR used in the discussed study is an exquisitely sensitive
assay for detecting methylation drift, it does not allow
determination of whether such methylation changes are pas-
senger versus driver genetic changes in BPH tissue.10 If
such hypermethylation-induced epigenetic silencing of the
SRD5A2 gene provided no growth advantage, then these
would be passenger changes and should be detected as
polyclonal variation within an epigenetic mosaicism in BPH
tissue. In contrast, if chronic inﬂammation-induced epige-
netic silencing of SRD5A2 drives neoplastic expansion of the
effected stem cells and their progeny, then it should be
detected as clonally derived. To resolve this issue of whether
the epigenetic silencing of SRD5A2 is a passenger versus
driver in the development of prostatic neoplasia, the clonality
of such SRD5A2 hypermethylation needs to be evaluated
using either bisulﬁte sequencing or methyl-binding
domainesingle-nucleotide polymorphism technology.13
This resolution is signiﬁcant for several reasons. First, the
stromal and epithelial compartments within the prostate are
organized via adult stem cell units.1 Second, chronic inﬂam-
mation occurs in>75%ofBPH tissues.14Combination of these
observations suggests that chronic inﬂammation could provide
a perfect storm for stochastic methylation drift-induced epige-
netic reprograming of stems cells within the prostate of aging
males, needed as a driver of neoplastic growth.
Therefore, it is important to point out that in the study by
Ge et al,10 transurethral resected BPH tissues were analyzed,
which contain both stromal and epithelial cells, and that in
the adult prostate, SRD5A2 gene is normally expressed by
both of these cell types.4,5 Thus, in the future studies, it will
be important to fractionate such BPH tissue to evaluate the
clonality of the CpG hypermethylationeinduced epigenetic
silencing of the SRD5A2 gene in both cell types. If it is
clonal in either of these cell types, this would strongly
suggest that down-regulation of SRD5A2 activity must have
a growth advantage for stem cells and their progeny within
the aging prostate. In addition, future studies need to eval-
uate whether the other SRD5A isoforms (ie, SRD5A1 and
SRD5A3) expressed in prostate tissue4,5 are also down-
regulated. This is particularly important, because recent
clinical trials have suggested that chronic (>5 years) treat-
ment of aging males with oral 5-a reductase inhibitors
decreases the incidence of low-grade (ie, Gleason score, 6),
but enhances the incidence of higher-grade (ie, Gleason
score, 7 to 10), localized prostate cancer.15The American Journal of Pathology - ajp.amjpathol.orgWhat Drives Chronic Inﬂammation in the
Prostate?
In addition to the ﬁndings of Olumi et al,10 other studies
also support the hypothesis that chronic inﬂammation in-
duces epigenetic reprogramming, resulting in a growth
advantage in both BPH and prostate cancer during aging.
With regard to the development of BPH, there is an increase
in the ratio of prostate stromal/epithelial area, going from a
3:1 ratio in nonhyperplastic normal prostates of young men
to a ratio of 5:1 in BPH tissue of older men.16 This change is
associated with an increase in cellular turnover in both the
stromal and epithelial compartments of BPH versus normal
prostate tissue.17 Two thirds of this stromal compartment in
BPH tissue is composed of smooth muscle (SM),18 and
BPH is associated with subtle epigenetic reprogramming in
the phenotype of these SM cells, as demonstrated by their
down-regulation in SM myosin heavy chain19 and up-
regulation of a2 macroglobulin mRNA expression.20 The
mechanism for such changes is not fully resolved, but it is
known that SM cells switch phenotype from contractive to
proliferative in response to extrinsic and/or intrinsic stimuli,
a process termed SM phenotype modulation.21
There are data supporting the concept that such SM pheno-
type modulation occurs in BPH due to a chronic immune in-
ﬂammatory process.22 This idea is based on the fact that nearly
all BPH specimens contain inﬂammatory inﬁltrates, but no
bacterial or foreign antigens have been identiﬁed.14,22 The
inﬁltrate consists predominantly of chronically activatedCD4þ
T lymphocytes, which are permanently recruited to prostate
tissue via elevated expression of IL-15 and interferon ɤ,
proinﬂammatory cytokines produced by prostate SM and
inﬁltrating T cells, respectively.22,23 Dysregulation of the im-
mune response in BPH is further compounded by elevated
expression of the proinﬂammatory IL-17 byT cells stimulating
enhanced production of IL-6 and IL-8, which themselves
stimulate stromal growth, further increasing IL-15 levels.22,23
These combinational events thus initiate a chronic inﬂamma-
tory process. Such a chronic inﬂammatory process ampliﬁes
disruption of the barrier function of the epithelial tight junc-
tions, allowingmore autoantigens (eg, prostate-speciﬁc antigen
and human glandular kallikrien-2) to leak into the prostate
stromal compartment, inducing a vicious cycle of chronic
inﬂammation within the prostate.24,25
In conclusion, such chronic inﬂammation provides both a
driving force for induction of epigenetic changes and a
selective microenvironment for the outgrowth of neoplastic
cells in the prostate of men as they age. Thus, inhibiting
such chronic inﬂammation within the prostate of aging
males is a promising approach for chemoprevention for both
BPH and prostate cancer.24,25
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